With the use of romosozumab, the development of hypocalcemia is a possible concern. Hypocalcemia should be corrected before initiation of treatment with romosozumab.

No dose adjustments are necessary for patients with renal impairment; however, patients with severe renal impairment or that are on dialysis are at increased risk for hypocalcemia and should be monitored closely.